Barriers to Tofersen Therapy for Variant <i>SOD1</i>-Mediated ALS

This Viewpoint advocates for the accelerated adoption of tofersen therapy to treat patients with variant SOD1 -mediated amyotrophic lateral sclerosis (ALS) and describes the current barriers to treatment.

Authors

Institutions

Publication Details

Journal
JAMA Neurology
Published
2024-10-07
DOI
https://doi.org/10.1001/jamaneurol.2024.3331
Citations
4
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
1.48
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS

Stanley H. Appel, Jason R. Thonhoff
4 citations
JAMA Neurology
Amyotrophic Lateral Sclerosis Research
1.48
article

Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS

Stanley H. Appel, Jason R. Thonhoff
article en
4 citations

Abstract

This Viewpoint advocates for the accelerated adoption of tofersen therapy to treat patients with variant SOD1 -mediated amyotrophic lateral sclerosis (ALS) and describes the current barriers to treatment.

JAMA NeurologyVol. 81(12)
Houston Methodist (US)
Good health and well-being
Openalex Percentile: Top 17%
Amyotrophic Lateral Sclerosis Research
1.48
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Barriers to Tofersen Therapy for Variant <i>SOD1</i>-Mediated ALS — Stanley H. Appel, Jason R. Thonhoff · JAMA Neurology (2024) | TGRS Research Map | TGRS